
Ana Sofia Ferreira
Advertisement
Articles by Ana Sofia Ferreira

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
3
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
4
Invasive Lobular Carcinoma: Diagnosis, Trials and What's Changing
5

![TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bb58c5f3c3692dc35c19320bb63c3df864f9b79b-1500x722.png?w=300&fit=crop&auto=format)